Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...

Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...

Advanced lung cancer, which has spread (metastasized) from the primary tumor to distant organs, is associated with lower survival rates. That's because lung cancer becomes more difficult to treat as ...

TORONTO — Five-year survival rates for people with lung cancer have doubled since the 1990s, but the disease still kills more patients than any other type of cancer, a Statistics Canada report said on ...

– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy ...

INSIGHT-003 is evaluating eftilagimod alpha (efti) in combination with the anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) and doublet chemotherapy as first-line treatment for patients with advanced or ...

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in the company's partner Summit ...

Merck & Co.’s subcutaneous (SC) formulation of Keytruda has matched up to the original intravenous (IV) version on two blood concentration measurements, paving way for a potential FDA approval that ...

Cap Stocks to Invest in According to Analysts. In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from two ...